Bristol-Myers Squibb  Note 2 BUSINESS SEGMENT INFORMATION  Upfront, pre-approval milestone and other licensing receipts obtained during development are deferred and amortized over the  estimated life of the product in other income. If the Company has no future obligation for development, upfront milestone and other licensing receipts are recognized immediately in other income. The amortization period of upfront, licensing and milestone receipts is  assessed and determined after considering terms of the arrangements.  BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale  of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply  chain organization are utilized and responsible for the development and delivery of products to the market. Regional commercial  organizations are used to distribute and sell the product. The business is also supported by global corporate staff functions. Segment  information is consistent with the financial information regularly reviewed by the chief operating decision maker, the chief executive  officer, for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and  forecasting future periods.  Products are sold principally to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government  agencies and pharmacies. Gross sales to the three largest pharmaceutical wholesalers in the U.S. as a percentage of global gross sales  were as follows:  Net sales of key products were as follows:  2012 2011 2010 McKesson Corporation 23 %  26 % 24 % Cardinal Health, Inc.  19 21 21 AmerisourceBergen Corporation  14 %  16 % 16 % Selected geographic area information was as follows:  Net Sales Property, Plant and Equipment  Dollars in Millions 2012  2011 2010 2012 2011 United States $^{(a)}$  $  10,384  $  14,039 $  12,800 $   4,464  $  3,538  Europe$^{(b)}$   3,706   3,879  3,672  740   886  Rest of the World$^{(c)}$   3,204   3,237  2,900  129   97  Other$^{(d)}$   327   89  112  -   -  Total  $  17,621  $  21,244 $  19,484 $   5,333  $  4,521  Year Ended December 31,  Dollars in Millions 2012 2011 2010 Plavix (clopidogrel bisulfate) $  2,547  $   7,087 $  6,666  Avapro/Avalide (irbesartan/irbesartan-hydrochlorothiazide)   503   952  1,176  Eliquis (apixaban)   2   -  -  Abilify (aripiprazole)   2,827   2,758  2,565  Reyataz (atazanavir sulfate)   1,521   1,569  1,479  Sustiva (efavirenz) Franchise   1,527   1,485   1,368  Baraclude (entecavir)   1,388   1,196  931  Erbitux (cetuximab)   702   691  662  Sprycel (dasatinib)  1,019   803  576  Yervoy (ipilimumab)  706   360  -  Orencia (abatacept)  1,176   917  733  Nulojix (belatacept)  11   3  -  Onglyza/Kombiglyze (saxagliptin/saxagliptin and metformin)  709   473  158  Byetta (exenatide)   149  N/A N/A Bydureon(exenatide extended-release for injectable suspension)   78  Mature Products and All Other   2,756   2,950  3,170  Net Sales $  17,621  $   21,244 $  19,484  (a) Includes Puerto Rico.  (b) Includes Russia and Turkey.  (c) Includes Japan, China, Canada, Australia and Brazil, among other countries.  (d) Includes royalty-related revenues and sales attributed to supply agreements.  36